Kaern J - Search Results

1

Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial.

Sorio R, Roemer-Becuwe C, Hilpert F, Gibbs E, García Y, Kaern J, Huizing M, Witteveen P, Zagouri F, Coeffic D, Lück HJ, González-Martín A, Kristensen G, Levaché CB, Lee CK, Gebski V, Pujade-Lauraine E; AURELIA Investigators. Sorio R, et al. Among authors: kaern j. Gynecol Oncol. 2017 Jan;144(1):65-71. doi: 10.1016/j.ygyno.2016.11.006. Epub 2016 Nov 18. Gynecol Oncol. 2017. PMID: 27871723 Clinical Trial.

2

Cisplatin/5-fluorouracil treatment of recurrent cervical carcinoma: a phase II study with long-term follow-up.

Kaern J, Tropé C, Sundfoer K, Kristensen GB. Kaern J, et al. Gynecol Oncol. 1996 Mar;60(3):387-92. doi: 10.1006/gyno.1996.0059. Gynecol Oncol. 1996. PMID: 8774643 Clinical Trial.

3

Effects of paclitaxel on CA-125 serum levels in ovarian cancer patients.

Paulsen T, Marth C, Kaern J, Nustad K, Kristensen GB, Tropé C. Paulsen T, et al. Among authors: kaern j. Gynecol Oncol. 2000 Mar;76(3):326-30. doi: 10.1006/gyno.1999.5699. Gynecol Oncol. 2000. PMID: 10684705 Clinical Trial.

4

Long-term results from a phase II study of paclitaxel combined with doxorubicin in recurrent platinum refractory ovarian cancer.

Tropé C, Kristensen G, Kisic J, Kaern J. Tropé C, et al. Among authors: kaern j. Eur J Gynaecol Oncol. 2001;22(3):223-7. Eur J Gynaecol Oncol. 2001. PMID: 11501778 Clinical Trial.

5

No prognostic impact of flow-cytometric measured DNA ploidy and S-phase fraction in cancer of the uterine cervix: a prospective study of 465 patients.

Kristensen GB, Kaern J, Abeler VM, Hagmar B, Tropé CG, Pettersen EO. Kristensen GB, et al. Among authors: kaern j. Gynecol Oncol. 1995 Apr;57(1):79-85. doi: 10.1006/gyno.1995.1102. Gynecol Oncol. 1995. PMID: 7705705

6

Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors.

Tropé C, Kaern J, Vergote IB, Kristensen G, Abeler V. Tropé C, et al. Among authors: kaern j. Gynecol Oncol. 1993 Nov;51(2):236-43. doi: 10.1006/gyno.1993.1279. Gynecol Oncol. 1993. PMID: 8276300 Review.

7

Malignant melanoma of the vulva FIGO stage I: Evaluation of prognostic factors in 43 patients with emphasis on DNA ploidy and surgical treatment.

Scheistrøen M, Tropé C, Kaern J, Abeler VM, Pettersen EO, Kristensen GB. Scheistrøen M, et al. Among authors: kaern j. Gynecol Oncol. 1996 May;61(2):253-8. doi: 10.1006/gyno.1996.0135. Gynecol Oncol. 1996. PMID: 8626143

8

Paclitaxel in untreated FIGO stage III suboptimally resected ovarian cancer.

Tropé C, Kaern J, Kristensen G, Rosenberg P, Sorbe B. Tropé C, et al. Among authors: kaern j. Ann Oncol. 1997 Aug;8(8):803-6. doi: 10.1023/a:1008230909599. Ann Oncol. 1997. PMID: 9332691 Free article. Clinical Trial.

9

The prognostic significance of surgery, tumor size, malignancy grade, menopausal status, and DNA ploidy in endometrial stromal sarcoma.

Nordal RR, Kristensen GB, Kaern J, Stenwig AE, Pettersen EO, Tropé CG. Nordal RR, et al. Among authors: kaern j. Gynecol Oncol. 1996 Aug;62(2):254-9. doi: 10.1006/gyno.1996.0224. Gynecol Oncol. 1996. PMID: 8751558

10

HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival.

Stavnes HT, Holth A, Don T, Kærn J, Vaksman O, Reich R, Trope' CG, Davidson B. Stavnes HT, et al. Among authors: kaern j. Gynecol Oncol. 2013 May;129(2):358-63. doi: 10.1016/j.ygyno.2013.02.021. Epub 2013 Feb 21. Gynecol Oncol. 2013. PMID: 23438671

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

114 results

Search Page